

7 February 2024

## Health House International provides additional A\$1m in revenue during January 2024

### Highlights:

- Health House International ('HHI') delivers A\$1m in unaudited revenue in January
- Revenue secured from HHI's relationships with customers in Australia, as well as UK operations
- Division's January revenue combined with recent sales via Mernova Medicinal Inc. take total revenue for Q1 FY24 to-date to over A\$2m, a run rate which exceeds Melodiol's record FY23 group revenue of A\$21.5m

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') is pleased to advise that 100%-owned operating division, Health House International Limited ('HHI' or 'HHI Australia') has generated A\$1m in unaudited revenue during January 2024.

HHI's unaudited revenue to date also adds to Mernova's A\$1m contribution (refer ASX announcement: 5 February 2024), taking total unaudited revenue for Q1 FY24 to date to over A\$2m, a run rate which exceeds record FY23 group revenue of A\$21.5m. This provides the company with a strong foundation for growth, which it intends to capitalise on in the coming months.

The division's January 2024 revenue was generated from HHI's established Australian business, as well as the division's operations in the United Kingdom.

HHI's ongoing contribution to the Company's revenue since its acquisition has further underpinned Melodiol's stated strategy of leveraging strategic M&A to fast track growth.

HHI personnel are advancing multiple sales initiatives to drive sales growth across key markets, while continuing to manage operating expenditure. The Company looks forward to providing further updates in the coming months as developments materialise.

### Management commentary:

**CEO and Managing Director, Mr William Lay said:** *"Health House has made a very valuable contribution to the Company's revenue profile in January, which based on recent sales from Mernova included now sits comfortably at over A\$2m. This has created a very strong foundation for Melodiol and we intend to capitalise on our growth trajectory aggressively over the coming months, pursuing multiple opportunities to unlock value for shareholders."*

*"We expect that both HHI and Mernova will continue to deliver sales in their key territories, where each division has longstanding relationships with customers. As well, the Company has defined a number of initiatives to further increase revenue."*

-Ends-

### Authority and Contact Details

This announcement has been authorised for release by the Disclosure Committee of Melodiol Global Health Limited.

For further information, please contact:

### Investor Enquiries

Melodiol Global Health Limited

E: [info@cresopharma.com](mailto:info@cresopharma.com)

P: +61 (0) 497 571 532

## About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

## Melodiol offices:

**Australia:** Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

**Canada:** 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

## Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.